title: Combining Ipilimumab and Bevacizumab in Glioblastoma: Is it Really Safe and Effective? Author Response.
authors.affiliation: UCL Cancer Institute, University College London, London, UK.
authors.forename: T
authors.initials: T
authors.lastname: Carter
authors.affiliation: University College London Hospitals, London, UK.
authors.forename: H
authors.initials: H
authors.lastname: Shaw
authors.affiliation: University College London Hospitals, London, UK; Mount Vernon Cancer Centre, Northwood, Middlesex, UK.
authors.forename: P
authors.initials: P
authors.lastname: Mulholland
mesh_terms: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D001932:Brain Neoplasms; D005909:Glioblastoma; D006801:Humans; D000074324:Ipilimumab; D009364:Neoplasm Recurrence, Local; D016896:Treatment Outcome
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D000074324:Ipilimumab; D000068258:Bevacizumab